特发性肺纤维化和间质性肺病前瞻性结果登记 (IPF/ILD-PRO)
特发性肺纤维化前瞻性结果 (IPF-PRO) 和慢性纤维化间质性肺病进展性表型前瞻性结果 (IPF-PRO/ILD-PRO) 注册
The Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry started recruiting in 2014 with the objective of studying Idiopathic Pulmonary Fibrosis. In 2018, the registry expanded to include recruitment of participants with other chronic fibrosing interstitial lung diseases (ILDs) with progressive phenotype also referred to as progressive fibrosing interstitial lung diseases in the Chronic Fibrosis Interstitial Lung Disease with Progressive Phenotype (ILD-PRO) Registry. When the third phase of the registry begins, the IPF-PRO registry will enroll additional patients with idiopathic pulmonary fibrosis. This IPF-PRO registry is a prospective registry that will collect information regarding the natural history, health care interactions, participant reported questionnaire data to assess quality of life, and the methods of treatment of participants with a diagnosis of idiopathic pulmonary fibrosis (IPF) or of another chronic fibrosing interstitial lung disease (ILD) with progressive phenotype established at the enrolling centers. In addition, blood samples and chest image studies will be collected and banked for future research projects.
研究概览
地位
详细说明
This registry originally enrolled a total of 1002 participants newly diagnosed with IPF and continues to enroll patients with other chronic fibrosing ILDs with newly identified progressive phenotype to reach an enrollment of 1000 patients. Participants will be enrolled in three phases, (IPF-PRO and ILD-PRO) over a span of 8 years at approximately 50 sites experienced in the diagnosis and treatment of ILD in the United States. Enrollment for the original IPF cohort started in 2014 and ended in October 2018, with 1002 total participants enrolled. In the third phase of the registry new enrollment for patients with IPF will restart in 2023-2024 with the plan to enroll up to 1000 new IPF patients, for a total IPF enrollment of 2000. Enrollment for other chronic fibrosing ILDs with newly identified progressive phenotype cohort was initiated in February 2019 and will end when enrollment reaches 1000 participants with the potential of enrolling another 1000 participants with other chronic fibrosing ILDs with newly identified without a progressive phenotype. Data and samples will be collected from participants for approximately 5 years for the IPF cohort. For the chronic fibrosing ILD with progressive phenotype cohort, data and samples will be collected for a minimum of 3 years, up to approximately 5 years. Participant management and treatment decisions will be determined by participants and their health care professionals.
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:Rosalia Blanco
- 电话号码:919-660-0890
- 邮箱:rosalia.blanco@duke.edu
学习地点
-
-
Alabama
-
Birmingham、Alabama、美国、35294
- 招聘中
- University of Alabama - Birmingham
-
首席研究员:
- Tejaswini Kulkarni, MD
-
接触:
- Arnissa Hopson
- 电话号码:205-934-1657
- 邮箱:agoggins@uabmc.edu
-
-
Arizona
-
Tucson、Arizona、美国、85721
- 招聘中
- University of Arizona
-
首席研究员:
- Sally A Suliman, MD
-
接触:
- Daniel Castaneda-Beltran
- 电话号码:602-827-2347
- 邮箱:dcastanedabeltra@arizona.edu
-
-
California
-
Los Angeles、California、美国、90033
- 招聘中
- University of Southern California
-
接触:
- Lynn Fukusima
- 邮箱:Lynn.Fukushima@med.usc.edu
-
首席研究员:
- Toby Maher, MD
-
Los Angeles、California、美国、90024
- 招聘中
- University of California - Los Angeles
-
首席研究员:
- John Belperio, MD
-
接触:
- Stephanie Roblero
- 电话号码:310-627-2319
- 邮箱:sroblero@mednet.ucla.edu
-
Stanford、California、美国、94305
- 招聘中
- Stanford University
-
首席研究员:
- Rishi Raj, MD
-
接触:
- Summer Zhu
- 电话号码:650-724-5424
- 邮箱:szhuye@stanford.edu
-
-
Colorado
-
Aurora、Colorado、美国、80045
- 招聘中
- University of Colorado
-
首席研究员:
- Joyce Lee, MD
-
接触:
- Olivia Brohl
- 电话号码:303-724-0641
- 邮箱:Olivia.brohl@cuanschutz.edu
-
-
Connecticut
-
New Haven、Connecticut、美国、06520
- 招聘中
- Yale University
-
首席研究员:
- Mridu Gulati, MD
-
接触:
- Maksym Minasyan
- 电话号码:203-785-4177
- 邮箱:maksym.minasyan@yale.edu
-
-
Florida
-
Gainesville、Florida、美国、32610-3175
- 招聘中
- University of Florida
-
接触:
- Lisbetty Lugo
- 邮箱:lisbetty.lugo@medicine.ufl.edu
-
首席研究员:
- Diana Gomez Manjarres, MD
-
Tampa、Florida、美国、33606
- 招聘中
- University of South Florida
-
首席研究员:
- Jose D Herazo-Maya, MD
-
接触:
- Natasha Brown
- 邮箱:nbrown@tgh.org
-
-
Georgia
-
Atlanta、Georgia、美国、30322
- 招聘中
- Emory University
-
接触:
- Tracy Halabi
- 电话号码:404-712-7458
- 邮箱:tracy.halaby@emory.edu
-
首席研究员:
- Srihari Veeraraghavan, MD
-
Austell、Georgia、美国、30106
- 招聘中
- Piedmont Healthcare
-
首席研究员:
- Amy Case, MD
-
接触:
- Munachi (Muna) Iwotor
- 电话号码:404-291-9062
- 邮箱:munachi.iwotor@piedmont.org
-
-
Illinois
-
Chicago、Illinois、美国、60637
- 招聘中
- University of Chicago
-
首席研究员:
- Mary Strek, MD
-
接触:
- Vanita Patel
- 邮箱:vpatel4@bsd.uchicago.edu
-
Evanston、Illinois、美国、60611
- 招聘中
- Northwestern University
-
接触:
- Phillip Cooper
- 电话号码:312-503-0406
- 邮箱:p-cooper@northwestern.edu
-
首席研究员:
- Bradford Bemiss, MD
-
Maywood、Illinois、美国、60153
- 招聘中
- Loyola University Health System
-
首席研究员:
- Daniel Dilling, MD
-
接触:
- Sloan White
- 邮箱:swhite29@luc.edu
-
-
Kansas
-
Kansas City、Kansas、美国、66160
- 终止
- University of Kansas
-
-
Kentucky
-
Lexington、Kentucky、美国、40536
- 招聘中
- University of Kentucky
-
首席研究员:
- Girish Nair, MD
-
接触:
- Kai Su
- 电话号码:859-257-4501
- 邮箱:kai.su@uky.edu
-
-
Louisiana
-
New Orleans、Louisiana、美国、70112
- 招聘中
- Tulane University
-
首席研究员:
- Joe Lasky, MD
-
接触:
- Sandy Ditta
- 电话号码:504-988-4040
- 邮箱:sditta@tulane.edu
-
-
Michigan
-
Ann Arbor、Michigan、美国、48109
- 主动,不招人
- University of Michigan
-
Detroit、Michigan、美国、48202
- 招聘中
- Henry Ford Health
-
接触:
- Deepti Naidu
- 电话号码:313-916-8732
- 邮箱:dnaidu1@HFHS.ORG
-
首席研究员:
- Asif Abdul Hameed, MD
-
-
Minnesota
-
Minneapolis、Minnesota、美国、55455
- 招聘中
- University of Minnesota
-
接触:
- Mandi DeGrote
- 电话号码:612-626-7609
- 邮箱:carl1032@umn.edu
-
首席研究员:
- Hyum Kim, MD
-
-
Mississippi
-
Jackson、Mississippi、美国、39216
- 招聘中
- University of Mississippi Medical Center
-
首席研究员:
- Kimberly Dobbs, MD
-
接触:
- Leadeashia Brackett
- 电话号码:601-496-7814
- 邮箱:lbrackett@umc.edu
-
-
Missouri
-
St Louis、Missouri、美国、63110
- 招聘中
- Washington University
-
首席研究员:
- Tonya Russell, MD
-
接触:
- Mona Noroozi
- 电话号码:314-362-3705
- 邮箱:mnoroozi@wustl.edu
-
-
New York
-
New York、New York、美国、10065
- 招聘中
- Weill Medical College of Cornell University
-
首席研究员:
- Kerri Aronson, MD
-
接触:
- Alicia Morris
- 电话号码:646-692-2741
- 邮箱:ajm2017@med.cornell.edu
-
New York、New York、美国、10016
- 主动,不招人
- NYU Medical Center
-
-
North Carolina
-
Chapel Hill、North Carolina、美国、27514
- 招聘中
- UNC Chapel Hill
-
首席研究员:
- Jason Lobo, MD
-
接触:
- Jackson Pettee
- 邮箱:Jackson_pettee@med.unc.edu
-
Durham、North Carolina、美国、27705
- 招聘中
- Duke University
-
首席研究员:
- Lake Morrison, MD
-
接触:
- Lauren Gray
- 电话号码:919-684-7317
- 邮箱:lauren.gray@duke.edu
-
Greensboro、North Carolina、美国、27403
- 招聘中
- Pulmonix LLC
-
首席研究员:
- Murali Ramaswamy, MD
-
接触:
- Mei Zheng
- 电话号码:336-522-8870
- 邮箱:mei.zheng@pulmonix.com
-
Wilmington、North Carolina、美国、28401
- 终止
- PMG Research
-
Winston-Salem、North Carolina、美国、27157
- 招聘中
- Wake Forest Baptist Health
-
接触:
- Bob Hmieleski
- 电话号码:336-713-8550
- 邮箱:bhmieles@wakehealth.edu
-
首席研究员:
- Andrew Namen, MD
-
-
Ohio
-
Cincinnati、Ohio、美国、45267
- 主动,不招人
- University of Cincinnati Medical Center
-
Cleveland、Ohio、美国、44195
- 招聘中
- Cleveland Clinic
-
首席研究员:
- Brian Southern, MD
-
接触:
- Ron Wehrmann
- 电话号码:2164450574
- 邮箱:wehrmar@ccf.org
-
Columbus、Ohio、美国、43210
- 招聘中
- The Ohio State University
-
接触:
- Benjamin Hood
- 邮箱:benjamin.hood2@osumc.edu
-
首席研究员:
- John Odackal
-
-
Oklahoma
-
Oklahoma City、Oklahoma、美国、73104
- 招聘中
- University of Oklahoma
-
首席研究员:
- Jad Kebbe, MD
-
接触:
- Maria Mason
- 电话号码:405-271-6173
- 邮箱:maria-l-mason@ouhsc.edu
-
-
Oregon
-
Portland、Oregon、美国、97220
- 招聘中
- Oregon Clinic
-
首席研究员:
- David Hotchkin, MD
-
接触:
- Meg Day
- 电话号码:503-963-3182
- 邮箱:mday@orclinic.com
-
-
Pennsylvania
-
Hershey、Pennsylvania、美国、17033
- 招聘中
- Penn State College of Medicine - Hershey
-
首席研究员:
- Rebecca Bascom, MD
-
接触:
- Tim Sheehan
- 电话号码:717-531-2925
- 邮箱:tsheehan@pennstatehealth.psu.edu
-
Philadelphia、Pennsylvania、美国、19140
- 招聘中
- Temple University
-
首席研究员:
- Rachel Criner, MD
-
接触:
- Luis Cardenas-Osorio
- 电话号码:215-707-3311
- 邮箱:Luis.Cardenas-Osorio@tuhs.temple.edu
-
Philadelphia、Pennsylvania、美国、19144
- 招聘中
- Thomas Jefferson University
-
首席研究员:
- Ross Summer, MD
-
接触:
- Ramya Talluri, BSN, RN
- 邮箱:RamyaPriya.Talluri@jefferson.edu
-
-
South Carolina
-
Charleston、South Carolina、美国、29425
- 招聘中
- Medical University of South Carolina
-
首席研究员:
- Timothy Whelan, MD
-
接触:
- Audra Wiser
- 邮箱:wisera@musc.edu
-
-
Tennessee
-
Nashville、Tennessee、美国、37232
- 招聘中
- Vanderbilt University
-
接触:
- James Del Greco
- 电话号码:615-343-7068
- 邮箱:james.del.greco@vumc.org
-
首席研究员:
- Justin Hewlett, MD
-
-
Texas
-
Dallas、Texas、美国、75235
- 招聘中
- University of Texas Southwestern
-
首席研究员:
- John Fitzgerald, MD
-
接触:
- Meagan Galvan
- 电话号码:214-645-6489
- 邮箱:Maegan.Galvan@UTSouthwestern.edu
-
Dallas、Texas、美国、75246
- 招聘中
- Baylor University Medical Center at Dallas
-
首席研究员:
- Yolanda Mageto, MD
-
接触:
- Mary Alayo
- 电话号码:214-820-6276
- 邮箱:Mary.Alayo@BSWHealth.org
-
Houston、Texas、美国、77030
- 招聘中
- Baylor College of Medicine
-
首席研究员:
- Ivan Rosas, MD
-
接触:
- Maria C Perea
- 邮箱:Maria.Perea@bcm.edu
-
Houston、Texas、美国、77030
- 招聘中
- Houston Methodist Lung Center
-
首席研究员:
- Zeenat Safdar, MD
-
接触:
- Laura Valecillos Loukidis
- 电话号码:346-238-4637
- 邮箱:lvvalecillosloukidis@houstonmethodist.org
-
Houston、Texas、美国、77030
- 招聘中
- The University of Texas Health Science Center At Houston
-
首席研究员:
- Rodeo Abrencillo, MD
-
接触:
- Beverly Rios
- 电话号码:713-486-6152
- 邮箱:Beverly.Rios@uth.tmc.edu
-
-
Utah
-
Salt Lake City、Utah、美国、84108
- 招聘中
- University of Utah
-
接触:
- Adeline Langer
- 电话号码:801-581-5811
- 邮箱:adeline.langer@hsc.utah.edu
-
首席研究员:
- Mary Beth Langer, MD
-
Salt Lake City、Utah、美国、84111
- 招聘中
- Intermountain Health
-
接触:
- Aisha Skowyra
- 电话号码:801-507-2439
- 邮箱:Aisha.fairclough@imail.org
-
首席研究员:
- Erin Blackstock, MD
-
-
Vermont
-
Colchester、Vermont、美国、05446
- 主动,不招人
- University of Vermont Lung Center
-
-
Virginia
-
Charlottesville、Virginia、美国、22908
- 主动,不招人
- University from Virginia
-
Falls Church、Virginia、美国、22042-3307
- 招聘中
- Inova Health Care Services
-
接触:
- Taruni Maganti
- 电话号码:703-776-3230
- 邮箱:Taruni.Maganti@inova.org
-
首席研究员:
- Jared Wilkinson, MD
-
-
Wisconsin
-
Milwaukee、Wisconsin、美国、53226
- 主动,不招人
- The Medical College of Wisconsin
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Subjects with a new diagnosis of IPF or a non- IPF chronic fibrosing ILD established at the time of enrollment in the registry are eligible for participation in the IPF-PRO/ILD-PRO registry if the participant meets the selection criteria.
描述
Inclusion Criteria:
-
Willing and able to provide informed consent
-
Established a new diagnosis (within 12 months) of IPF by the enrolling center.
-
Age 21 years or older, or
-
Diagnosis of a non-IPF ILD of any duration, including, but not limited to Idiopathic Non-Specific Interstitial Pneumonia (iNSIP), Unclassifiable Idiopathic Interstitial Pneumonias (IIPs), Interstitial Pneumonia with Autoimmune Features (IPAF), Autoimmune ILDs such as Rheumatoid Arthritis (RA-ILD) and Systemic Sclerosis (SSc-ILD), Chronic Hypersensitivity Pneumonitis (HP), Sarcoidosis or Exposure-related ILDs such as asbestosis with progressive phenotype during the last 24 months by the enrolling center that meets the following criteria:
-
Chronic fibrosing ILD as defined by reticular abnormality with traction bronchiectasis with or without honeycombing confirmed by chest HRCT scan and/or lung biopsy.
-
Progressive phenotype as defined by fulfilling at least one of the criteria below of fibrotic changes (progression set point) within the last 24 months regardless of treatment considered appropriate in individual ILDs (8):
- decline in FVC % predicted (% pred) based on ≥10% relative decline
- decline in FVC % pred based on ≥5 - <10% relative decline in FVC combined with worsening of respiratory symptoms as assessed by the site investigator
- decline in FVC % pred based on ≥5 - <10% relative decline in FVC combined with increasing extent of fibrotic changes on chest imaging (HRCT scan) as assessed by the site investigator
- decline in DLCO % pred based on≥ 10% relative decline
- worsening of respiratory symptoms as well as increasing extent of fibrotic changes on chest imaging (HRCT scan) as assessed by the site investigator independent of FVC change.
-
The relative decline for FVC % predicted is calculated using the formula:
Relative Decline= (FVC % Pred (Reference)-FVC % Pred (Screening))/(FVC % Pred (Reference))×100%, where FVC % Pred (Reference) is the greatest measurement of FVC % predicted in the 24 months prior to screening and FVC % Pred (Screening) is the measurement of FVC % predicted at screening.
The relative decline for DLCO % predicted is calculated using the formula:
Relative Decline= (DLCO % Pred (Reference)-DLCO % Pred (Screening))/(DLCO % Pred (Reference))×100%, Where DLCO % Pred (Reference) is the greatest measurement of DLCO % Pred in the 24 months prior to screening and DLCO % Pred (Screening) is the measurement of DLCO % Pred at screening
Exclusion Criteria:
- Malignancy, treated or untreated, other than skin or early -stage prostate cancer, within the past 5 years
- Currently listed for lung transplantation at the time of enrollment
- Currently enrolled in an interventional clinical trial at the time of enrollment in this registry
- For the additional IPF cohort of 1000 individuals, previous enrollment in this registry.
学习计划
研究是如何设计的?
设计细节
- 观测模型:COHORT
- 时间观点:PROSPECTIVE
队列和干预
团体/队列 |
|---|
|
Subjects with a new IPF diagnosis
Subjects with a new diagnosis of IPF established at the time of enrollment in the registry |
|
Subjects with a non-IPF ILD diagnosis
Subjects with a diagnosis of a non-IPF ILD of any duration, including, but not limited to Idiopathic Non-Specific Interstitial Pneumonia (iNSIP), Unclassifiable Idiopathic Interstitial Pneumonias (IIPs), Interstitial Pneumonia with Autoimmune Features (IPAF), Autoimmune ILDs such as Rheumatoid Arthritis (RA-ILD) and Systemic Sclerosis (SSc-ILD), Chronic Hypersensitivity Pneumonitis (HP), Sarcoidosis or Exposure-related ILDs such as asbestosis with progressive phenotype |
|
New Subjects with a new IPF diagnosis
Subjects with a new diagnosis of IPF established at the time of enrollment in the registry not previously enrolled in the registry. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Data on natural history of IPF & non-IPF chronic fibrosing ILD
大体时间:End of Study (3 years after last patient will be enrolled)
|
Characterize and describe the natural history of patients with a recent confirmed diagnosis of IPF, with emphasis on demographics, co-morbidities, medications, and risks for disease progression or death. |
End of Study (3 years after last patient will be enrolled)
|
|
Data on current practice patterns for diagnosis of IPF & non-IPF chronic fibrosing ILD
大体时间:End of Study (3 years after last patient will be enrolled)
|
Understand the current practice patterns for diagnosis of IPF & non-IPF chronic fibrosing ILD |
End of Study (3 years after last patient will be enrolled)
|
|
Data on impact of IPF & non- IPF chronic fibrosing ILD on patient quality of life.
大体时间:End of Study (3 years after last patient will be enrolled)
|
Describe the impact of IPF & non- IPF chronic fibrosing ILD on patient quality-of-life (QOL). |
End of Study (3 years after last patient will be enrolled)
|
|
Blood samples for future research.
大体时间:End of Study (3 years after last patient will be enrolled)
|
Collect longitudinal bio-samples for future research on disease presentation, progression, and subject response to clinical interventions. |
End of Study (3 years after last patient will be enrolled)
|
|
HRCT images for future research (for non-IPF chronic fibrosing ILD, and new IPF patients cohort)
大体时间:End of Study (3 years after last patient will be enrolled)
|
Collect longitudinal HRCT images for future research |
End of Study (3 years after last patient will be enrolled)
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Data on management practices compared to existing guidelines.
大体时间:End of Study (3 years after last patient will be enrolled)
|
Compare disease-specific management practices with existing guidelines. |
End of Study (3 years after last patient will be enrolled)
|
|
Data on center-specific practices on outcomes.
大体时间:End of Study (3 years after last patient will be enrolled)
|
Determine the influence of center-specific practices on patient outcomes. |
End of Study (3 years after last patient will be enrolled)
|
合作者和调查者
调查人员
- 首席研究员:Scott Palmer, MD、Duke Clinical Research Institute, Duke University
出版物和有用的链接
一般刊物
- Swaminathan AC, Hellkamp AS, Neely ML, Bender S, Paoletti L, White ES, Palmer SM, Whelan TPM, Dilling DF; Idiopathic Pulmonary Fibrosis Prospective Outcomes Registry investigators. Disparities in Lung Transplant among Patients with Idiopathic Pulmonary Fibrosis: An Analysis of the IPF-PRO Registry. Ann Am Thorac Soc. 2022 Jun;19(6):981-990. doi: 10.1513/AnnalsATS.202105-589OC.
- Kim HJ, Snyder LD, Neely ML, Hellkamp AS, Hotchkin DL, Morrison LD, Bender S, Leonard TB, Culver DA; IPF-PRO Registry investigators. Clinical Outcomes of Patients with Combined Idiopathic Pulmonary Fibrosis and Emphysema in the IPF-PRO Registry. Lung. 2022 Feb;200(1):21-29. doi: 10.1007/s00408-021-00506-x. Epub 2022 Jan 7.
- de Andrade JA, Kulkarni T, Neely ML, Hellkamp AS, Case AH, Culver DA, Guntupalli K, Bender S, Conoscenti CS, Snyder LD; IPF-PRO Registry Investigators. Associations between resources and practices of ILD centers and outcomes in patients with idiopathic pulmonary fibrosis: data from the IPF-PRO Registry. Respir Res. 2022 Jan 7;23(1):3. doi: 10.1186/s12931-021-01921-7.
- Kim HJ, Snyder LD, Adegunsoye A, Neely ML, Bender S, White ES, Conoscenti CS, Strek ME; IPF-PRO Registry Investigators. Hospitalizations in patients with idiopathic pulmonary fibrosis. Respir Res. 2021 Sep 30;22(1):257. doi: 10.1186/s12931-021-01851-4.
- Salisbury ML, Conoscenti CS, Culver DA, Yow E, Neely ML, Bender S, Hartmann N, Palmer SM, Leonard TB; IPF-PRO Registry principal investigators as follows. Antifibrotic Drug Use in Patients with Idiopathic Pulmonary Fibrosis. Data from the IPF-PRO Registry. Ann Am Thorac Soc. 2020 Nov;17(11):1413-1423. doi: 10.1513/AnnalsATS.201912-880OC.
- Fan Y, Bender SD, Conoscenti CS, Davidson-Ray L, Cowper PA, Palmer SM, de Andrade JA; IPF-PRO Registry Investigators. Hospital-Based Resource Use and Costs Among Patients With Idiopathic Pulmonary Fibrosis Enrolled in the Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry. Chest. 2020 Jun;157(6):1522-1530. doi: 10.1016/j.chest.2019.12.041. Epub 2020 Jan 29.
- O'Brien EC, Hellkamp AS, Neely ML, Swaminathan A, Bender S, Snyder LD, Culver DA, Conoscenti CS, Todd JL, Palmer SM, Leonard TB; IPF-PRO Registry investigators. Disease Severity and Quality of Life in Patients With Idiopathic Pulmonary Fibrosis: A Cross-Sectional Analysis of the IPF-PRO Registry. Chest. 2020 May;157(5):1188-1198. doi: 10.1016/j.chest.2019.11.042. Epub 2020 Jan 15.
- Todd JL, Neely ML, Overton R, Durham K, Gulati M, Huang H, Roman J, Newby LK, Flaherty KR, Vinisko R, Liu Y, Roy J, Schmid R, Strobel B, Hesslinger C, Leonard TB, Noth I, Belperio JA, Palmer SM; IPF-PRO Registry investigators. Peripheral blood proteomic profiling of idiopathic pulmonary fibrosis biomarkers in the multicentre IPF-PRO Registry. Respir Res. 2019 Oct 22;20(1):227. doi: 10.1186/s12931-019-1190-z.
- Snyder L, Neely ML, Hellkamp AS, O'Brien E, de Andrade J, Conoscenti CS, Leonard T, Bender S, Gulati M, Culver DA, Kaner RJ, Palmer S, Kim HJ; IPF-PRO Registry investigators. Predictors of death or lung transplant after a diagnosis of idiopathic pulmonary fibrosis: insights from the IPF-PRO Registry. Respir Res. 2019 May 30;20(1):105. doi: 10.1186/s12931-019-1043-9.
- O'Brien EC, Durheim MT, Gamerman V, Garfinkel S, Anstrom KJ, Palmer SM, Conoscenti CS. Rationale for and design of the Idiopathic Pulmonary Fibrosis-PRospective Outcomes (IPF-PRO) registry. BMJ Open Respir Res. 2016 Jan 11;3(1):e000108. doi: 10.1136/bmjresp-2015-000108. eCollection 2016.
- Swaminathan AC, Weber JM, Todd JL, Palmer SM, Neely ML, Whelan TP, Kim GHJ, Leonard TB, Goldin J. Extent of lung fibrosis is of greater prognostic importance than HRCT pattern in patients with progressive pulmonary fibrosis: data from the ILD-PRO registry. Respir Res. 2025 Feb 28;26(1):73. doi: 10.1186/s12931-025-03136-6.
- Oldham JM, Neely ML, Wojdyla DM, Gulati M, Li P, Patel DC, Palmer SM, Todd JL; IPF-PRO Registry Investigators. Changes in Lung Function and Mortality Risk in Patients With Idiopathic Pulmonary Fibrosis. Chest. 2025 Aug;168(2):415-422. doi: 10.1016/j.chest.2025.02.018. Epub 2025 Feb 26.
- Sack C, Wojdyla DM, MacMurdo MG, Gassett A, Kaufman JD, Raghu G, Redlich CA, Li P, Olson AL, Leonard TB, Todd JL, Neely ML, Snyder LD, Gulati M; IPF-PRO Registry investigators. Long-Term Air Pollution Exposure and Severity of Idiopathic Pulmonary Fibrosis: Data from the Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry. Ann Am Thorac Soc. 2025 Mar;22(3):378-386. doi: 10.1513/AnnalsATS.202404-382OC.
- Wang L, Wu P, Liu Y, Patel DC, Leonard TB, Zhao H. Clustering-aided prediction of outcomes in patients with idiopathic pulmonary fibrosis. Respir Res. 2024 Oct 23;25(1):383. doi: 10.1186/s12931-024-03015-6.
- Lobo LJ, Liu Y, Li P, Ramaswamy M, Swaminathan AC, Veeraraghavan S, Fan Y, Neely ML, Palmer SM, Olson AL; ILD-PRO Registry investigatorsdagger. Design and baseline characteristics of the ILD-PRO registry in patients with progressive pulmonary fibrosis. BMC Pulm Med. 2024 Sep 27;24(1):468. doi: 10.1186/s12890-024-03247-8.
- Summer R, Todd JL, Neely ML, Lobo LJ, Namen A, Newby LK, Shafazand S, Suliman S, Hesslinger C, Keller S, Leonard TB, Palmer SM, Ilkayeva O, Muehlbauer MJ, Newgard CB, Roman J. Circulating metabolic profile in idiopathic pulmonary fibrosis: data from the IPF-PRO Registry. Respir Res. 2024 Jan 25;25(1):58. doi: 10.1186/s12931-023-02644-7.
- Neely ML, Hellkamp AS, Bender S, Todd JL, Liesching T, Luckhardt TR, Oldham JM, Raj R, White ES, Palmer SM. Lung function trajectories in patients with idiopathic pulmonary fibrosis. Respir Res. 2023 Aug 24;24(1):209. doi: 10.1186/s12931-023-02503-5.
- Ruan P, Todd JL, Zhao H, Liu Y, Vinisko R, Soellner JF, Schmid R, Kaner RJ, Luckhardt TR, Neely ML, Noth I, Porteous M, Raj R, Safdar Z, Strek ME, Hesslinger C, Palmer SM, Leonard TB, Salisbury ML. Integrative multi-omics analysis reveals novel idiopathic pulmonary fibrosis endotypes associated with disease progression. Respir Res. 2023 May 31;24(1):141. doi: 10.1186/s12931-023-02435-0.
- Menon AA, Gansen B, Mulder H, Neely ML, Papavasileiou P, Salisbury ML, Southern BD, Hesslinger C, Leonard TB, Meissner F, Todd JL. Mass spectrometry-based peripheral blood proteomics for biomarker discovery in idiopathic pulmonary fibrosis. Respir Res. 2025 Oct 22;26(1):294. doi: 10.1186/s12931-025-03377-5.
- Shetty S, Swaminathan AC, Li P, Neely ML, Olson AL, Snyder LD; ILD-PRO Registry investigators. Workplace Productivity Loss in Patients with Progressive Pulmonary Fibrosis: Data from the ILD-PRO Registry. Lung. 2026 May 27;204(1):32. doi: 10.1007/s00408-026-00895-x.
- Swaminathan AC, Mulder H, Neely ML, Schmid R, Belperio JA, Patel NM, Palmer SM, Todd JL. Expression of complement pathway genes is associated with progression of idiopathic pulmonary fibrosis. Respir Res. 2026 Mar 25;27(1):196. doi: 10.1186/s12931-026-03641-2.
- Neely ML, Todd JL, Snyder LD, Li P, Olson AL; IPF-PRO Registry Investigators *. Trajectories of Health-Related Quality of Life in Patients With Idiopathic Pulmonary Fibrosis. CHEST Pulm. 2024 Dec 27;3(4):100133. doi: 10.1016/j.chpulm.2024.100133. eCollection 2025 Dec.
- MacMurdo MG, Wojdyla DM, Gassett A, Kaufman JD, Raghu G, Redlich CA, Patel DC, Neely ML, Snyder LD, Gulati M, Sack C; IPF-PRO Registry investigators. Short-term air pollution exposure and hospitalizations in idiopathic pulmonary fibrosis: data from the IPF-PRO Registry. Ann Am Thorac Soc. 2026 Sep 12:aaoag285. doi: 10.1093/annalsats/aaoag285. Online ahead of print.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.